Develops, manufactures and sells pharmaceutical formulations across respiratory, cardiac, anti-diabetes and other chronic therapies. In FY26 the business reported two segments: Pharmaceuticals (₹20,617.25 cr, 94.6% of segment revenue) and New ventures (₹1,175.86 cr, 5.4%). The Pharmaceuticals segment covers India branded prescription drugs (One India crossed ₹12,500 cr for the first time, growing 9% YoY), North America generics ($780 mn in FY26; 186 approved ANDAs with 48 under approval; US #1 in Albuterol MDI with 21% share), and One Africa ($483 mn, growing at 1.4x the South African market). New ventures houses newer businesses such as biosimilars, where 1–2 products are to be added per year for the next 5–6 years through the Kemwell joint venture. R&D spend was ₹1,974 cr (7% of FY26 revenue), funding a complex respiratory and peptide pipeline; a US generic Ventolin launch commenced in Q1 FY27 with 6-month competitive generic therapy exclusivity. The largest FY26 cost lines were materials at 20.7% of revenue, employees at 19.1%, and other opex at 26.1%, with capex at 5.7%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceuticals (95%), New ventures (5%). Diversified, R&D-intensive Indian pharma major with a global generics footprint weighted to chronic and respiratory therapies.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 |
| EBITDA (ex other income) | 4,371 | 4,845 | 6,096 | 7,128 | 5,607 |
| margin % | 20.1 | 21.3 | 23.7 | 25.9 | 19.9 |
| Owners' profit | 2,517 | 2,802 | 4,122 | 5,273 | 3,879 |
| EPS, as reported (₹) | 31.20 | 34.72 | 51.05 | 65.29 | 48.03 |
| ROE % · ROCE % | 12.1 · 16.2 | 11.9 · 17.0 | 15.5 · 21.1 | 16.8 · 21.6 | 11.2 · 14.9 |
| Debt / equity (x) | 0.04 | 0.02 | 0.01 | 0.00 | 0.01 |
| Cash from operations | 3,326 | 3,238 | 4,134 | 5,005 | 3,940 |
| Capex | (544) | (841) | (1,098) | (1,162) | (1,599) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 |
| Profit before tax | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 |
| Net profit | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 |
| EPS (₹) | 16.13 | 19.45 | 15.13 | 16.07 | 16.73 | 8.37 | 6.87 | 9.77 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals | 20,617 | 94.6 |
| New ventures | 1,176 | 5.4 |
| Total, before eliminations | 21,793 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · Cipla partners with Qilu for US biosimilar to Keytruda | strategic transactions | high | — | — |
| 3 Sept 2026 · NCLT notice sent for Inzpera Healthsciences amalgamation with Cipla | general | low | — | — |
| 2 Sept 2026 · Cipla informs shareholders about SEBI special window for physical share transfer | compliance | minimal | — | — |
| 31 Aug 2026 · Cipla signs exclusive licensing deal with SBP Group for HER2 ADC TQB2102 | strategic transactions | high | — | — |
| 28 Aug 2026 · Cipla InvaGen US facility classified VAI by USFDA after inspection | regulatory legal | high | — | — |
| 27 Aug 2026 · Cipla group simplifies ownership of US unit Aspergen Inc. | strategic transactions | medium | — | — |
| 27 Aug 2026 · Cipla schedules analyst meetings at Jefferies India Forum and Kotak Healthcare conference | board shareholder meetings | low | — | — |
| 26 Aug 2026 · Cipla allots 5281 shares under ESOP and ESAR schemes | capital market events | low | — | — |
| 25 Aug 2026 · USFDA inspection at Pithampur facility yields 7 observations | regulatory legal | high | — | — |
| 19 Aug 2026 · NCLT allows Cipla to absorb wholly-owned subsidiary Inzpera Healthsciences | regulatory legal | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 2,47,033 |
| 84.6 |
| 14.74 |
| 63.7 |
| 15.3 |
| 18.8 |
| 8.7 |
| 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD ◆ | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 32.7 | 28.9 | 91 of 169 | 46% |
| P/B | 3.2 | 3.3 | 80 of 163 | 51% |
| ROCE | 14.7 | 10.8 | 67 of 183 | 64% |
| ROE | 11.2 | 10.4 | 81 of 171 | 53% |
| Debt / Equity | 0.0 | 0.1 | 49 of 171 | 72% |
| EBITDA margin | 19.7 | 17.5 | 76 of 165 | 54% |
| Revenue growth | 2.3 | 16.3 | 121 of 161 | 25% |
| Profit growth | (39.2) | 30.9 | 126 of 158 | 20% |
| Market cap | 110352 | 839 | 5 of 182 | 98% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
